Editorial
Split Viewer
Korean J Hematol 2012; 47(3):
Published online September 25, 2012
https://doi.org/10.5045/kjh.2012.47.3.157
© The Korean Society of Hematology
Targeting the protein kinases for anti-cancer therapy
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Noble, ME, Endicott, JA, Johnson, LN. Protein kinase inhibitors: insights into drug design from structure. Science, 2004;303;1800-1805.
- Zhang, J, Yang, PL, Gray, NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 2009;9;28-39.
- Paul, MK, Mukhopadhyay, AK. Tyrosine kinase - role and significance in cancer. Int J Med Sci, 2004;1;101-115.
- Hennessy, BT, Smith, DL, Ram, PT, Lu, Y, Mills, GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov, 2005;4;988-1004.
- Farag, SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol, 2011;155;561-579.
- Sasai, K, Katayama, H, Stenoien, DL, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton, 2004;59;249-263.
- Katayama, H, Sasai, K, Kawai, H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet, 2004;36;55-62.
- Kim, SJ, Jang, JE, Cheong, JW, et al. Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells. Korean J Hematol, 2012;47;178-185.
- Kantarjian, HM, Sekeres, MA, Ribrag, V, et al. Phase I study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside in patients with acute myeloid leukemia (AML). Blood, 2010;116;abst656.
PDF
Standard view
Export citation
Share Article
Editorial
Korean J Hematol 2012; 47(3): 157-158
Published online September 25, 2012 https://doi.org/10.5045/kjh.2012.47.3.157
Copyright © The Korean Society of Hematology.
Targeting the protein kinases for anti-cancer therapy
Soo-Mee Bang, M.D.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Noble, ME, Endicott, JA, Johnson, LN. Protein kinase inhibitors: insights into drug design from structure. Science, 2004;303;1800-1805.
- Zhang, J, Yang, PL, Gray, NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 2009;9;28-39.
- Paul, MK, Mukhopadhyay, AK. Tyrosine kinase - role and significance in cancer. Int J Med Sci, 2004;1;101-115.
- Hennessy, BT, Smith, DL, Ram, PT, Lu, Y, Mills, GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov, 2005;4;988-1004.
- Farag, SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol, 2011;155;561-579.
- Sasai, K, Katayama, H, Stenoien, DL, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton, 2004;59;249-263.
- Katayama, H, Sasai, K, Kawai, H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet, 2004;36;55-62.
- Kim, SJ, Jang, JE, Cheong, JW, et al. Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells. Korean J Hematol, 2012;47;178-185.
- Kantarjian, HM, Sekeres, MA, Ribrag, V, et al. Phase I study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside in patients with acute myeloid leukemia (AML). Blood, 2010;116;abst656.
Previous Article
